Pulmonary Arterial Hypertension Market (By Drug Class: Prostacyclin and Prostacyclin Analogs, Soluble Guanylate Cyclase (SGC) Stimulators, Endothelin Receptor Antagonists (ERA), Phosphodiesterase 5 (PDE-5)) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook 20212030

·         Chapter 1.  Introduction

·         1.1.  Research Objective

·         1.2.  Scope of the Study

·         1.3.  Definition

·         Chapter 2.  Research Methodology

·         2.1.  Research Approach

·         2.2.  Data Sources

·         2.3.  Assumptions & Limitations

·         Chapter 3.  Executive Summary

·         3.1.  Market Snapshot

·         Chapter 4.  Market Variables and Scope

·         4.1.  Introduction

·         4.2.  Market Classification and Scope

·         4.3.  Industry Value Chain Analysis

·         4.3.1.    Raw Material Procurement Analysis

·         4.3.2.    Sales and Distribution Channel Analysis

·         4.3.3.    Downstream Buyer Analysis

·         Chapter 5.  Market Dynamics Analysis and Trends

·         5.1.  Market Dynamics

·         5.1.1.    Market Drivers

·         5.1.2.    Market Restraints

·         5.1.3.    Market Opportunities

·         5.2.  Porter’s Five Forces Analysis

·         5.2.1.    Bargaining power of suppliers

·         5.2.2.    Bargaining power of buyers

·         5.2.3.    Threat of substitute

·         5.2.4.    Threat of new entrants

·         5.2.5.    Degree of competition

·         Chapter 6.  Competitive Landscape

·         6.1.1.    Company Market Share/Positioning Analysis

·         6.1.2.    Key Strategies Adopted by Players

·         6.1.3.    Vendor Landscape

·         6.1.3.1.        List of Suppliers

·         6.1.3.2.        List of Buyers

·         Chapter 7.  Global Pulmonary Arterial Hypertension Market, By Drug Class

·         7.1.  Pulmonary Arterial Hypertension Market, By Drug Class Type, 2020-2030

·         7.1.1.    Prostacyclin and Prostacyclin Analogs

·         7.1.1.1.        Market Revenue and Forecast (2016-2030)

·         7.1.2.    Soluble Guanylate Cyclase (SGC) Stimulators

·         7.1.2.1.        Market Revenue and Forecast (2016-2030)

·         7.1.3.    Endothelin Receptor Antagonists (ERA)

·         7.1.3.1.        Market Revenue and Forecast (2016-2030)

·         7.1.4.    Phosphodiesterase 5 (PDE-5)

·         7.1.4.1.        Market Revenue and Forecast (2016-2030)

·         Chapter 8.  Global Pulmonary Arterial Hypertension Market, Regional Estimates and Trend Forecast

·         8.1.  North America

·         8.1.1.    Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.1.2.    U.S.

·         8.1.3.    Rest of North America

·         8.1.3.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.2.  Europe

·         8.2.1.    Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.2.2.    UK

·         8.2.2.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.2.3.    France

·         8.2.3.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.2.4.    Rest of Europe

·         8.2.4.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.3.  APAC

·         8.3.1.    Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.3.2.    India

·         8.3.2.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.3.3.    China

·         8.3.3.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.3.4.    Japan

·         8.3.4.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.3.5.    Rest of APAC

·         8.3.5.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.4.  MEA

·         8.4.1.    Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.4.2.    GCC

·         8.4.2.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.4.3.    North Africa

·         8.4.3.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.4.4.    South Africa

·         8.4.4.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.4.5.    Rest of MEA

·         8.4.5.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.5.  Latin America

·         8.5.1.    Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.5.2.    Brazil

·         8.5.2.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         8.5.3.    Rest of LATAM

·         8.5.3.1.        Market Revenue and Forecast, By Drug Class (2016-2030)

·         Chapter 9.    Company Profiles

·         9.1.  PAH include GlaxoSmithKline plc

·         9.1.1.    Company Overview

·         9.1.2.    Product Offerings

·         9.1.3.    Financial Performance

·         9.1.4.    Recent Initiatives

·         9.2.  Johnson & Johnson Services

·         9.2.1.    Company Overview

·         9.2.2.    Product Offerings

·         9.2.3.    Financial Performance

·         9.2.4.    Recent Initiatives

·         9.3.  United Therapeutics Corporation

·         9.3.1.    Company Overview

·         9.3.2.    Product Offerings

·         9.3.3.    Financial Performance

·         9.3.4.    Recent Initiatives

·         9.4.  Pfizer, Inc.

·         9.4.1.    Company Overview

·         9.4.2.    Product Offerings

·         9.4.3.    Financial Performance

·         9.4.4.    Recent Initiatives

·         9.5.  Gilead Sciences, Inc.

·         9.5.1.    Company Overview

·         9.5.2.    Product Offerings

·         9.5.3.    Financial Performance

·         9.5.4.    Recent Initiatives

·         Chapter 10.  Research Methodology

·         10.1.              Primary Research

·         10.2.              Secondary Research

·         10.3.              Assumptions

·         Chapter 11.  Appendix

·         11.1.              About Us

·         Glossary of Terms